Assess the Efficacy and Safety of Personalized Prophylaxis Human-cl rhFVIII in Patients With Severe Haemophilia A
2020年12月21日 更新者:Octapharma
Prospective, Open-label, Multi-centre Phase 3b Study to Assess the Efficacy and Safety of Personalized Prophylaxis With Human-cl rhFVIII in Previously Treated Adult Patients With Severe Haemophilia A
The rationale of this study is to further fine-tune and individualize prophylactic treatment of patients with severe Haemophilia A with the goal of keeping the trough FVIII level above 1% between doses.
Because trough FVIII levels are likely to be important predictors of the efficacy of prophylaxis, the focus of this study is on pharmacokinetic (PK) data.
研究概览
研究类型
介入性
注册 (实际的)
58
阶段
- 第三阶段
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
-
Zagreb、克罗地亚
- University Hospital Centre Zagreb
-
-
-
-
Alberta
-
Edmonton、Alberta、加拿大、T6G1C9
- Octapharma Research Site
-
-
Newfoundland and Labrador
-
St. John's、Newfoundland and Labrador、加拿大
- Octapharma Research Site
-
-
Ontario
-
Hamilton、Ontario、加拿大、L8N 4K1
- McMaster University
-
-
-
-
-
Skopje、北马其顿
- PHI Institute of Transfusion Medicine of Republic of Macedonia
-
-
-
-
-
Ljubljana、斯洛文尼亚
- University Medical Centre Ljubljana
-
-
-
-
-
Maebashi、日本
- Gunma University Hospital
-
Osaka、日本
- Osaka National Hospital
-
Tokyo、日本
- Ogikubo Hospital
-
Tokyo、日本
- Teikyo University Hospital
-
-
Aichi
-
Nagoya、Aichi、日本
- Nagoya University Hospital
-
-
Fukuoka
-
Kitakyushu、Fukuoka、日本
- Hospital of the Univ of Occupational and Environmental Health
-
-
Kanagawa
-
Kawasaki、Kanagawa、日本
- St. Marianna Univ School of Medicine Hospital
-
-
Nara
-
Kashihara、Nara、日本
- Nara Medical University Hospital
-
-
-
-
-
Bron、法国、69677
- Centre régional de traitement de l'Hémophilie
-
Clermont-Ferrand、法国
- CHU Estaing
-
La Réunion、法国、97400
- Centre Hospitalier Universitaire Félix Guyon
-
Nantes、法国、44093
- Centre régional de traitement de l'Hémophilie
-
Toulouse、法国、31059
- Hôpital Purpan - Centre de Traitment Regional de l'Hemophilie Pole
-
-
-
-
California
-
Sacramento、California、美国、95817
- Octapharma Research Site
-
-
Colorado
-
Aurora、Colorado、美国、80045
- Octapharma Research Site
-
-
District of Columbia
-
Washington、District of Columbia、美国、20057
- Octapharma Research Site
-
-
Florida
-
Miami、Florida、美国、33136
- Octapharma Research Site
-
-
Illinois
-
Chicago、Illinois、美国、60612
- Octapharma Research Site
-
-
Indiana
-
Indianapolis、Indiana、美国、46260
- Octapharma Research Site
-
-
Tennessee
-
Memphis、Tennessee、美国、38163
- Octapharma Research Site
-
-
Texas
-
Houston、Texas、美国、77030
- Octapharma Research Site
-
-
Utah
-
Salt Lake City、Utah、美国、84112
- Octapharma Research Site
-
-
-
-
-
Helsinki、芬兰、00290
- Helsinki University Hospital
-
-
-
-
-
Groningen、荷兰、9713
- University Medical Center Groningen
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 及以上 (成人、年长者)
接受健康志愿者
不
有资格学习的性别
男性
描述
Inclusion Criteria:
- Severe Haemophilia A (FVIII:C < 1%)
- Male patients >= 18 years of age
- Previous treatment with a FVIII concentrate for at least 150 EDs
- Good documentation regarding dosing and bleeding frequency in the 6 months preceding study start
- Immunocompetence (CD4+ count > 200/uL)
Exclusion Criteria:
- Any coagulation disorder other than Haemophilia A
- Present of past FVIII inhibitor activity
- Severe liver or kidney disease
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:预防
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
实验性的:人-cl rhFVIII
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Annualized Total Bleeding Rate of Individually Tailored Prophylaxis
大体时间:6 months
|
Total annualized bleeding rate (ABR) of individually tailored prophylaxis (GENA-21b) compared to historical bleeding rate in patients having received on-demand treatment (GENA-01) with Human-cl rhFVIII
|
6 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Annualized Spontaneous Bleeding Rate of Individually Tailored Prophylaxis
大体时间:6 months
|
Spontaneous annualized bleeding rate (ABR) of individually tailored prophylaxis (GENA-21b) compared to historical bleeding rate in patients having received on-demand treatment (GENA-01) with Human-cl rhFVIII
|
6 months
|
Annualized Total Bleeding Rate in Patients With 2x/Week (or Less) Prophylaxis
大体时间:6 months
|
Total annualized bleeding rate (ABR) in patients with 2x/week (or less) prophylaxis (GENA-21b) compared to historical bleeding rate in patients having received on-demand treatment (GENA-01) with Human-cl rhFVIII
|
6 months
|
Median Prophylactic Dosing Interval
大体时间:6 months
|
Median over median actual dosing intervals between two prophylactic treatments per patient.
The median time (hours) between two prophylactic doses of Human-cl rhFVIII in the prophylactic treatment Phase II per patient
|
6 months
|
Mean Prophylactic Dosing Interval
大体时间:6 months
|
Mean over mean actual dosing intervals between two prophylactic treatments per patient.
The mean time (hours) between two prophylactic doses of Human-cl rhFVIII in the prophylactic treatment Phase II per patient
|
6 months
|
AUC Divided by the Dose (AUCnorm) of Human-cl rhFVIII
大体时间:Before injection (within 1 h before injection) and up to 72 h (± 2 h) after the end of injection
|
AUCnorm of Human-cl rhFVIII measured using the one-stage (OS) assay
|
Before injection (within 1 h before injection) and up to 72 h (± 2 h) after the end of injection
|
In-vivo Recovery (IVR) of Human-cl rhFVIII
大体时间:Before injection (within 1 h before injection) and up to 72 h (± 2 h) after the end of injection
|
IVR of Human-cl rhFVIII measured using the one-stage (OS) assay and will be determined from the FVIII level before the infusion and the peak level after the infusion of Human-cl rhFVIII
|
Before injection (within 1 h before injection) and up to 72 h (± 2 h) after the end of injection
|
Half Life (t1/2) of Human-cl rhFVIII
大体时间:Before injection (within 1 h before injection) and up to 72 h (± 2 h) after the end of injection
|
T1/2 of Human-cl rhFVIII measured using the one-stage (OS) assay
|
Before injection (within 1 h before injection) and up to 72 h (± 2 h) after the end of injection
|
Mean Residence Time (MRT) of Human-cl rhFVIII
大体时间:Before injection (within 1 h before injection) and up to 72 h (± 2 h) after the end of injection
|
MRT of Human-cl rhFVIII measured using the one-stage (OS) assay
|
Before injection (within 1 h before injection) and up to 72 h (± 2 h) after the end of injection
|
Clearance (CL) of Human-cl rhFVIII
大体时间:Before injection (within 1 h before injection) and up to 72 h (± 2 h) after the end of injection
|
CL of Human-cl rhFVIII measured using the one-stage (OS) assay
|
Before injection (within 1 h before injection) and up to 72 h (± 2 h) after the end of injection
|
Volume of Distribution at Steady State (Vss) of Human-cl rhFVIII
大体时间:Before injection (within 1 h before injection) and up to 72 h (± 2 h) after the end of injection
|
Vss of Human-cl rhFVIII measured using the one-stage (OS) assay
|
Before injection (within 1 h before injection) and up to 72 h (± 2 h) after the end of injection
|
Usage of Human-cl rhFVIII (FVIII IU/kg BW Per Week Per Patient)
大体时间:6 months
|
Average weekly consumption of Human-cl rhFVIII reported as IU/kg BW per week per patient was determined during individualized prophylactic treatment
|
6 months
|
Number of Patients With Adverse Events (AEs)
大体时间:At each study visit over the study duration (7-9 months)
|
AEs were documented at each (scheduled or unscheduled) study visit.
Severity and seriousness of all AEs were documented by the investigator according to pre-defined criteria
|
At each study visit over the study duration (7-9 months)
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
赞助
调查人员
- 首席研究员:Craig M Kessler, MD、Georgetown University
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2015年5月1日
初级完成 (实际的)
2018年9月1日
研究完成 (实际的)
2018年9月1日
研究注册日期
首次提交
2014年9月30日
首先提交符合 QC 标准的
2014年10月1日
首次发布 (估计)
2014年10月6日
研究记录更新
最后更新发布 (实际的)
2021年1月19日
上次提交的符合 QC 标准的更新
2020年12月21日
最后验证
2020年12月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
严重血友病 A的临床试验
-
Cheikh Anta Diop University, SenegalInternational Atomic Energy Agency尚未招聘
-
University of California, DavisBill and Melinda Gates Foundation; Penn State University; Newcastle University; Helen Keller International 和其他合作者完全的
-
Ionis Pharmaceuticals, Inc.Akcea Therapeutics完全的
-
Institute of Nutrition of Central America and PanamaBill and Melinda Gates Foundation; Newcastle University; International Atomic Energy Agency完全的
-
Medical University of Vienna完全的
-
Tufts UniversityNutricia Research Fundation; National University of Science and Technology, Zimbabwe完全的
人类 cl rhFVIII的临床试验
-
Octapharma完全的
-
Octapharma完全的
-
Octapharma完全的严重血友病 A加拿大, 美国, 法国, 西班牙, 乌克兰, 英国, 白俄罗斯, 乔治亚州, 德国, 印度, 意大利, 摩尔多瓦共和国, 摩洛哥, 波兰, 葡萄牙, 俄罗斯联邦, 斯洛文尼亚
-
Arash Asher, MDVoxxLife招聘中
-
Imperial College LondonCambridge University Hospitals NHS Foundation Trust; University of Edinburgh; University of Manchester 和其他合作者终止